Merck's tulisokibart met phase 2b endpoints in hidradenitis suppurativa

Merck said tulisokibart met its primary and key secondary endpoints in a phase 2b study in patients with moderate to severe hidradenitis suppurativa. The company said the data will inform phase 3 development and showed comparable safety with placebo.